Please login to the form below

Not currently logged in
Email:
Password:

FDA approves drug for drooling

The US Food and Drug Administration has approved Shionogi Pharma's Cuvposa oral solution to treat chronic severe drooling in children

The US Food and Drug Administration (FDA) has approved Shionogi Pharma's Cuvposa (glycopyrrolate) oral solution to treat chronic severe drooling in children who suffer from neuromuscular dysfunction related to neurologic disorders. The drug is cleared for children aged three years to 16 years.

Glycopyrrolate, which was cleared for US marketing decades ago in tablet form as a treatment for peptic ulcers, was already frequently used off-label for the paediatric drooling indication, as it lowers the volume of saliva produced in the mouth.

The new approval is the result of a 2001 advisory committee meeting convened by the FDA "to discuss how best to develop products for drooling with ethically and scientifically sound trials in children who have neurological disorders," the agency said.

Cuvposa is a flavoured oral solution designed for ease of use in paediatric patients. When the drug was used off-label, the tablets had to be crushed and mixed with fluid, which was unpalatable to some children and also often resulted in inexact dosing.

Clinical trials of Cuvposa showed that 78 per cent of the children taking the active drug had clinical improvement in drooling, versus 19 per cent of the placebo group.

29th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics